Novel potent and selective inhibitors of p90 ribosomal S6 kinase reveal the heterogeneity of RSK function in MAPK-driven cancers.
Aronchik, I., Appleton, B.A., Basham, S.E., Crawford, K., Del Rosario, M., Doyle, L.V., Estacio, W.F., Lan, J., Lindvall, M.K., Luu, C.A., Ornelas, E., Venetsanakos, E., Shafer, C.M., Jefferson, A.B.(2014) Mol Cancer Res 12: 803-812
- PubMed: 24554780 
- DOI: 10.1158/1541-7786.MCR-13-0595
- Primary Citation of Related Structures:  
4NUS - PubMed Abstract: 
The p90 ribosomal S6 kinase (RSK) family of serine/threonine kinases is expressed in a variety of cancers and its substrate phosphorylation has been implicated in direct regulation of cell survival, proliferation, and cell polarity. This study characterizes and presents the most selective and potent RSK inhibitors known to date, LJH685 and LJI308 ...